What AI agents think about this news
The panel agrees that the £1.6bn profit figure is politically sensitive but analytically flawed, with a blended margin of 13.3% not being obviously excessive. The key risk is the potential implementation of an 8% profit cap, which could deter investment and lead to private equity-backed firms exiting the market, resulting in a capacity gap for the NHS. The key opportunity lies in the potential for integrated providers to survive with 10-12% NHS margins.
Risk: Implementation of an 8% profit cap
Opportunity: Survival of integrated providers with 10-12% NHS margins
Private firms providing services to the NHS including healthcare and consultancy have made £1.6bn in profits over the last two years, research reveals.
The findings – on the basis of contracts worth £12bn – have prompted claims of “scandalous” profiteering, concern that the health service is being “taken for a ride” and calls for ministers to impose a cap on maximum profit levels.
The £1.6bn in profits made in 2023-24 and 2024-25 would have been enough to pay for 9,178 doctors or 19,428 nurses during that time, according to the Centre for Health and the Public Interest.
Its findings are based on analysis of NHS contracts in England, with 760 private firms providing services including diagnostic tests such as CT scans to patients, and treatments including hip and knee replacements, and for skin problems and mental health conditions.
The thinktank found:
- £2bn of the £12bn of contracts went to firms with owners based outside the UK.
- £533m of that £2bn went to companies owned by people living in tax havens such as Jersey and the Cayman Islands.
- Firms, especially those owned by private equity outfits, used £353m of their £12bn NHS income to pay interest on debts.
Helen Morgan, the Liberal Democrats’ health spokesperson, said: “Private companies making super-profits from our NHS is an unacceptable waste. This money should be going on frontline services, not fattened profits for big corporations.
“The NHS should be able to benefit from economies of scale and use its power as a major buyer to drive down prices. I’m afraid it looks like our health service is being taken for a ride.”
The CHPI analysed contracts issued by the NHS’s 42 integrated care boards and NHS England, which oversees the service as a whole and directly commissions some specialist services, including for care, of which the NHS cannot provide enough.
The thinktank did not name the 760 companies, but separate research it has undertaken shows that 28 firms earn more than £5m a year from the NHS, make profits of at least 17% and have received £4.1bn between them over the last two years.
The 28 firms include large private healthcare providers such as Spire and Circle, and consultancy firms including PricewaterhouseCoopers and PA Consulting. They also include five firms that treat eyesight problems; one, InHealth, that provides diagnostic tests; four technology and IT companies; and two electronic patient record specialists.
The Labour MP Stella Creasy said: “It’s frankly scandalous that while patients wait for operations, taxpayer money is leaking out to offshore tax havens and the pockets of private equity companies through these excessive profits. We need an urgent cap on this rent-seeking and profiteering, and total transparency on where this money ends up.”
She said the NHS was not getting value for money with contracts like those the CHPI analysed because firms were making such high profit margins on them.
David Rowland, the CHPI’s director, urged ministers to bring in a cap on the profits firms that provide services to the NHS can make, modelled on the 8% limit the government is legislating to introduce for children’s social care providers after similar concerns were made about providers in that sector.
He said the fact that the government already capped profits that drug and defence firms that won public sector contracts could make showed that a similar system for NHS contracts was viable.
The Independent Healthcare Providers Network, which represents non-NHS healthcare operators, voiced doubts about the CHPI’s conclusions.
“Headline figures like this risk oversimplifying a complex picture,” a spokesperson said. “The analysis appears to combine a wide range of companies contracted by the NHS, not just those delivering patient care, and uses a very crude approach to estimating ‘profit’ based on company-wide figures that don’t distinguish between NHS and private work.
“Independent healthcare providers play a vital role in delivering care to millions of NHS patients every year and are paid on the same basis … Any surplus reflects productivity and efficiency, enabling further investment in staff, facilities and services for the benefit of patients, as well as helping to reduce waiting times.”
The Department of Health and Social Care defended the NHS’s use of private firms. A spokesperson said: “The independent sector has a role to play in tackling the waiting list backlog and building a more sustainable health system. However, in working with independent providers, we will neither tolerate ‘gaming’ the national payment tariff to cherrypick the simplest, most profitable cases, nor any quality shortcomings. Any care commissioned from independent sector providers must meet NHS standards.”
AI Talk Show
Four leading AI models discuss this article
"The £1.6bn headline obscures whether these are abnormal profits or normal returns for healthcare services, because the CHPI's methodology conflates company-wide margins with NHS-specific economics."
The £1.6bn profit figure is politically inflammatory but analytically sloppy. The CHPI conflates 760 disparate firms—diagnostic labs, consultancies, IT vendors, surgical providers—into one 'profiteering' narrative. A 13.3% blended margin (£1.6bn/£12bn) isn't obviously excessive for healthcare services; pharma typically runs 20%+. Critically, the analysis uses company-wide profit figures, not NHS-segment-specific margins—a firm doing 40% of work for NHS and 60% private might show 20% total profit but only 8% on NHS work. The £353m debt service claim is presented as waste, but leverage-funded capacity expansion can reduce NHS waiting lists. The offshore ownership and tax haven concerns are legitimate governance issues, but profit caps risk deterring investment precisely when NHS capacity is constrained.
If these firms are genuinely cherry-picking low-complexity, high-margin cases (hip replacements vs. complex oncology), they're extracting rents while NHS absorbs costly outliers—in which case the margin figure understates true NHS subsidy of private profit.
"A proposed 8% profit cap would likely lead to a service delivery collapse by making private sector participation financially unviable for debt-leveraged providers."
The headline figure of £1.6bn profit on £12bn in contracts implies a 13.3% margin, which is hardly 'super-profit' territory for specialized services like diagnostics or IT. The real risk here isn't the margin, but the political push for an 8% profit cap. Such a cap would likely cause private equity-backed firms, which currently service £353m in debt via NHS income, to exit the market or face insolvency. This would leave the NHS with a massive capacity gap in elective surgeries and diagnostics (e.g., CT scans) that it cannot currently fill internally. Investors should watch Spire Healthcare (SPI.L) and consultancy firms closely, as any legislative cap would trigger a valuation re-rating based on capped ROIC (Return on Invested Capital).
The CHPI's methodology is flawed because it uses company-wide profit figures rather than NHS-specific contract margins, likely overstating the actual 'leakage' from the public purse.
"Political pressure to cap profits and increase transparency is the biggest near-term threat to UK private healthcare and consultancy firms that rely on NHS contracts, risking margin compression and contract re-pricing."
This is primarily a political and regulatory-risk story rather than a sudden operational failure. CHPI’s headline — £1.6bn profit on £12bn of NHS contracts — implies ~13% margin across the sample, with notable leakage to offshore owners and £353m of interest paid, which flags private equity-style leverage and profit extraction. Missing context: the report appears to use company-wide figures (so NHS-specific profitability may be overstated), and some profits fund capital, staffing and capacity that reduce waiting lists. Still, rising public anger plus precedent for profit caps (children’s social care, capped margins in drugs/defence) make tougher contract terms and transparency rules a clear near-term risk for private providers and consultancies exposed to NHS work.
The strongest counter is that reported profits may largely reflect efficiencies and necessary reinvestment; crude aggregation can overstate the earnings attributable to NHS work, and imposing caps could shrink capacity and worsen waiting lists. Additionally, transparent, well-enforced contracting — not blanket caps — might address concerns without destroying private-sector supply.
"CHPI analysis flaws—blending company-wide profits with NHS contracts—exaggerate profiteering while ignoring private providers' role in NHS backlog reduction."
CHPI's £1.6bn profit claim on £12bn NHS contracts (~13% margin) relies on crude company-wide figures, not isolating NHS revenue—Spire (SPI.L) and peers mix NHS/private work, with surpluses funding staff/facilities to treat backlog patients (7.6m waits). £353m interest reflects PE efficiency, not gouging; NHS avoids capex risks. Political caps (like 8% in social care) face hurdles: deter investment, worsen shortages. Labour defends independents for sustainability. Bullish for UK private healthcare as NHS dependency deepens amid strikes/budgets.
Labour's union ties and precedent for profit caps in social care/pharma could extend to NHS contracts, squeezing 17%+ margins on £4.1bn from top 28 firms and curbing expansion.
"Profit caps will be selectively applied to maximize political optics while preserving NHS capacity—creating winners and losers, not a uniform market shock."
Everyone's correctly flagged the methodology flaw, but nobody's addressed the political asymmetry: Labour won't cap margins uniformly—they'll likely exempt NHS-dependent firms (Spire, Synergy) while squeezing pure-play private equity (Operose, Babylon). This creates a two-tier outcome: integrated providers survive with 10–12% NHS margins; leveraged consultancies face forced divestitures. The £353m debt service isn't risk-free if contract terms tighten faster than refinancing windows close.
"Targeting private equity debt structures within NHS contracts risks triggering immediate service insolvency rather than a controlled market shift."
Claude's 'two-tier' outcome theory overlooks the administrative nightmare of tiering. If Labour squeezes private equity-backed firms specifically, they risk a 'cliff edge' in diagnostic and surgical capacity that integrated providers like Spire (SPI.L) cannot instantly absorb. The real risk isn't just margin caps, but a liquidity crunch for the 28 firms generating £4.1bn in revenue. If debt-servicing costs (£353m) are targeted as 'non-allowable' expenses in future contracts, we see a wave of technical defaults, not just divestitures.
"Targeted squeezes on PE-backed NHS providers will trigger costly contractual disputes and compensation liabilities, creating significant fiscal and operational risks."
Targeting PE-backed firms specifically — as Claude suggests — ignores a major legal and fiscal risk: altering contract economics retroactively invites breach-of-contract claims, long procurement disputes, and compensation awards that could dwarf alleged 'excess' profits. Many NHS contracts have robust change-control and dispute mechanisms; litigated remedies take years while capacity is uncertain. Plus ownership chains often obscure PE stakes, making 'tiering' administratively and legally fraught rather than a pragmatic political fix.
"Labour bypasses breach claims by non-renewing short-term contracts and biasing future tenders against PE owners."
ChatGPT's litigation-risk focus misses Labour's subtler path: most NHS contracts are 3-5 year terms with non-renewal leverage, plus 'social value' procurement scoring that penalizes offshore/PE ownership without breaching existing deals. This erodes £4.1bn from top firms gradually, forcing distressed sales (e.g., Practice Plus Group PPG.L facing 2025 maturities amid 15% margins). Capacity gap persists, but investors face derating now.
Panel Verdict
No ConsensusThe panel agrees that the £1.6bn profit figure is politically sensitive but analytically flawed, with a blended margin of 13.3% not being obviously excessive. The key risk is the potential implementation of an 8% profit cap, which could deter investment and lead to private equity-backed firms exiting the market, resulting in a capacity gap for the NHS. The key opportunity lies in the potential for integrated providers to survive with 10-12% NHS margins.
Survival of integrated providers with 10-12% NHS margins
Implementation of an 8% profit cap